PaxMedica Inc. Common Sto... (PXMD)
0.00
-0.00 (-100.00%)
At close: Feb 27, 2025, 3:00 PM
0.10
99900.00%
Pre-market: Nov 29, 2024, 09:30 AM EST
No 1D chart data available
| Bid | n/a |
| Market Cap | 1.09K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.1M |
| EPS (ttm) | -2.77 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.03 |
| Analyst | n/a |
| Ask | n/a |
| Volume | 157 |
| Avg. Volume (20D) | 30,402 |
| Open | 0.00 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 1.19 |
| Beta | -0.56 |
About PXMD
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomi...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2022
Employees 6
Stock Exchange NASDAQ
Ticker Symbol PXMD
Website https://www.paxmedica.com
10 months ago
+21.2%
PaxMedica shares are trading higher after the comp...
Unlock content with
Pro Subscription
10 months ago
-10.81%
PaxMedica shares are trading higher after the company received an emergency request form the Ministry of Health of Malawi, asking for emergency access to IV suramin.
